BTI 320

Drug Profile

BTI 320

Alternative Names: BTI-320; PAZ-320

Latest Information Update: 18 Oct 2016

Price : $50

At a glance

  • Originator Boston Therapeutics
  • Developer Advance Pharmaceutical Co Ltd; Boston Therapeutics
  • Class Antihyperglycaemics; Mannans
  • Mechanism of Action Alpha-glucosidase inhibitors; Amylase inhibitors; Carbohydrate metabolism inhibitors; Glucose modulators; Hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus

Most Recent Events

  • 13 Oct 2016 Advance Pharmaceutical completes a phase II trial in Type-2 diabetes mellitus in Hong Kong prior to October 2016 (9205112; NCT02358668)
  • 07 Oct 2015 Boston Therapeutics completes enrolment in its phase-II trial for Type-2 diabetes mellitus in Hong Kong (PO)
  • 15 Sep 2015 Interim efficacy data from a phase-II trial in Type-2 diabetes mellitus released by Boston Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top